Michael Almstetter, CEO
CEO since the formation of Origenis in 2005, leading the company through growth and private financing rounds. Michael created the basis for the later MOREsystem® with the invention of MolMind®. He also is responsible for the development of parallel chemistry, automated synthesis and analytics.He studied chemistry at the Technical University of Munich at the Organic Chemistry department of Prof. Dr. Ivar Ugi.
Dr Michael Thormann, CSO
Michael Thormann is co-founder and co-inventor of MOREsystem® and MolMind®. He leads the technology platform development, implementation, and its application throughout the drug discovery and development process. As CSO, he is responsible for the success of the cross-functional, highly interdisciplinary team and empowers scientific excellence and technological leadership, and industrial applicability. Prior Origenis, as Head of Molecular Modeling at Morphochem, he invented protein- and ligand-based drug design methods, QSPR, parallel evolutionary search algorithms, and multiparametric optimization techniques, that together with Cippix® and BRAINstorm® have lead to Origenis’ proprietary AI Innovation Platform. He received his Ph.D. in biochemistry from the University of Leipzig in 1998. He worked in the field of secondary structure design and conformational analysis of special non-natural peptides and held several post-doctoral positions at the University of Barcelona and Polytechnical University of Catalonia.
Dr Andreas Treml, COO
Andreas Treml helms and oversees business operations, HR and manages budget and financial goals. As co-founder of Origenis he is contributing biological expertise to the management team. In prior positions he was responsible for assay development and integrating ‘New Technologies’ for parallel biological characterization. Andreas holds a Ph.D. in biology and worked in the field of steroid hormone receptors and transcription factors for therapeutic oncology and across multiple therapeutic target areas during industrial and academic collaborations.
Dr Peter Seufer-Wasserthal, CBO
Dr. Seufer-Wasserthal brings 25 years’ experience in technology-oriented business development to the company. Prior to joining Origenis, he served as Vice President Business Development at Intrexon Corporation (NYSE: XON) and before that held several senior executive and business development positions at Codexis, Inc., (NASDAQ: CDXS), where he closed numerous licensing, research and supply agreements. Before Codexis, Dr. Seufer-Wasserthal managed a broad range of drug discovery collaborations, licensed pre-clinical candidates to Pharma partners and directed several drug development projects in the position of Senior Vice President of Business Development at Morphochem and Evotec.